Drug Interactions
Tirzepatide is a large peptide eliminated by proteolysis and albumin-mediated catabolism — it is not metabolised by CYP450 enzymes and is not renally cleared. This pharmacokinetic profile means the classical drug-drug interaction mechanisms (CYP inhibition/induction, renal competition) do not apply. The FDA Mounjaro prescribing information (2024/2026 updates) confirms no dose adjustment is required in renal or hepatic impairment, including end-stage renal disease (ESRD), and no formal CYP-based DDI studies are required. However, two interaction mechanisms are clinically relevant: gastric emptying delay affecting oral drug absorption, and emerging case-level evidence for warfarin and levothyroxine.
Gastric emptying delay — the main mechanism: Tirzepatide’s GLP-1 receptor agonism delays gastric emptying (a pharmacological class effect). Phase 1 PK studies embedded in SURPASS programme assessed the effect on acetaminophen as a gastric emptying probe:
- Single-dose (5mg): acetaminophen Cmax reduced approximately 50% and Tmax delayed — a substantial PK effect on an orally-absorbed marker drug
- After 4 weeks at dose: the effect on acetaminophen Cmax was no longer statistically significant — consistent with tachyphylaxis of the gastric-emptying effect seen with GLP-1 RA class drugs after repeated dosing
- Clinical implication: the gastric emptying delay is most pronounced in the first few weeks of treatment and with dose escalation. Drugs with narrow therapeutic indices taken as immediate-release formulations are at greatest risk during initiation and up-titration periods.
Ontology Drug Interactions [relates] Tirzepatide Drug Interactions [relates] Side Effects Profile Drug Interactions [relates] GLP-1 Receptor Agonism
Warfarin — case report signal (PMC 12503860, 2025): A published case report described a patient with a mechanical heart valve on stable warfarin anticoagulation who started tirzepatide. Within 10 days of initiating tirzepatide, INR dropped below therapeutic range. The proposed mechanism: reduced oral warfarin absorption or altered vitamin K absorption via gastric emptying delay and GI motility changes. A second hypothesis is altered hepatic metabolism from rapid weight loss (fat-soluble vitamin K stores mobilised). The case does not establish causality — it is a single report — but the narrow therapeutic index of warfarin and the severe consequences of subtherapeutic INR (mechanical valve thrombosis) make this signal clinically actionable.
Practical recommendation from the case report: INR should be monitored more frequently during the first 4–8 weeks of tirzepatide initiation in patients on warfarin. Dose adjustment may be required.
Ontology Drug Interactions [relates] Hypoglycaemia Risk
Levothyroxine — patient-reported signal: Multiple UK HealthUnlocked and NHS patient reports describe the need for levothyroxine dose adjustment after starting tirzepatide. The proposed mechanism is twofold: (1) weight loss reduces total body T4 requirement, independent of drug interaction; (2) gastric emptying delay may reduce peak levothyroxine absorption (levothyroxine requires absorption in the upper small intestine, and it should be taken fasting — delayed gastric emptying could theoretically reduce Cmax). No formal PK interaction study for levothyroxine and tirzepatide has been published. The EMA and FDA labels do not flag this interaction. TSH monitoring at 3–6 months after tirzepatide initiation is prudent in hypothyroid patients.
FDA label (2024/2026) summary on interactions:
- No dose adjustment for renal impairment (including ESRD — not renally cleared)
- No dose adjustment for hepatic impairment
- No CYP-based interactions described
- Gastric emptying delay flagged for concomitant oral medications — stated that co-administered oral drugs should be monitored for clinical effect changes, particularly during initiation
- No specific interactions listed in the DDI section beyond the gastric emptying pharmacodynamic interaction class
Interaction Risk Summary
| Drug/Class | Mechanism | Evidence Level | Clinical Action |
|---|---|---|---|
| Warfarin | Gastric emptying / possible malabsorption | Case report (low) | Monitor INR closely at initiation; expect possible dose adjustment |
| Levothyroxine | Weight loss + possible absorption delay | Patient reports (very low) | Monitor TSH at 3–6 months; adjust dose if TSH rises |
| Narrow-TI oral drugs (tacrolimus, digoxin) | Gastric emptying delay on Cmax | Phase 1 proxy (acetaminophen) | Monitor drug levels during initiation; use TDM |
| Oral contraceptives | Gastric emptying delay | Theoretical; not studied | Manufacturer advises barrier contraception for 4 weeks after new GI symptom period or dose escalation |
| Metformin | None (metformin PK unaffected by GLP-1 RA) | Established | No interaction; combine freely |
| Insulin / sulphonylurea | Pharmacodynamic: additive glucose lowering | Established from trials | Reduce insulin 20% at initiation; monitor for hypoglycaemia |
Connections
- Side Effects Profile — relates (GI mechanism drives pharmacokinetic interactions)
- GLP-1 Receptor Agonism — class effect (gastric emptying delay)
- NHS Patient Experience UK — levothyroxine signal source
- Tirzepatide — parent note